Digital recruitment and compliance to treatment recommendations in the Norwegian Atrial Fibrillation self-screening pilot study.

Atrial fibrillation (AF) is prevalent, undiagnosed in approximately one-third of cases, and is associated with severe complications. Guidelines recommend screening individuals at increased risk of stroke. This report evaluated the digital recruitment procedure and compliance with the follow-up recommendations in participants with screen-detected AF in the Norwegian Atrial Fibrillation self-screening pilot study. Norwegians ≥65 years were invited through Facebooks posts, web pages, and newspapers to participate in the study. Targeted Facebook posts promoted over 11 days reached 84 208 users and 10 582 visitors to the study homepage. This accounted for 51% of the total homepage visitors ( Digital recruitment and inclusion in digital AF screening with a high rate of initiation of anticoagulation therapy in AF positive screening cases are feasible. However, digital recruitment and inclusion may introduce selection bias with regard to age and gender. Larger studies are needed to determine the efficacy and cost-effectiveness of a fully digital AF screening. Clinical trials: NCT04700865.

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.

Déclaration de conflit d'intérêts

Conflict of interest: E.L.S. has received speaking fees from Pfizer and AstraZeneca. S.H. has received speaking fees from Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, and Sanofi unrelated to this work. T.B. has received speaking fees from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, and Pfizer. J.G. has received speaking fees from Bayer, Boehringer-Ingelheim, Novartis and Sanofi, and fees for participating in an expert panel from Sanofi, unrelated to this work. D.A. has received speaker fees from Amarin, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer-Ingelheim, Merck & Co., Novartis, Pfizer, Pharmacosmos, Philips, Sanofi and Vifor, as well as research funding to his institution from Bristol Myers Squibb, Pfizer, Medtronic, and Roche Diagnostics. He acts as scientific advisor to Appsens AS. B.L.G. has received speaking fees from Bristol Myers Squibb, Pfizer, Novartis, Astra Zeneca, Boehringer Ingelheim, and Bayer. J.J. has received speaking fees from Amarin, Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Novartis, Pfizer, and Sanofi. He is shareholder in Appsens AS and is employed in the company.